Rxivist logo

Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021

By David A Swan, Ashish Goyal, Chloe Bracis, Mia Moore, Elizabeth Krantz, Elizabeth R. Brown, Fabian Cardozo-Ojeda, Daniel B Reeves, Fei Gao, Peter B Gilbert, Lawrence Corey, Myron Cohen, Holly Janes, Dobromir Dimitrov, Joshua T Schiffer

Posted 14 Dec 2020
medRxiv DOI: 10.1101/2020.12.13.20248120

Ongoing SARS-CoV-2 vaccine trials assess vaccine efficacy against disease (VEDIS), the ability of a vaccine to block symptomatic COVID-19. They will only partially discriminate whether VEDIS is mediated by preventing infection as defined by the detection of virus in the airways (vaccine efficacy against infection defined as VESUSC), or by preventing symptoms despite breakthrough infection (vaccine efficacy against symptoms or VESYMP). Vaccine efficacy against infectiousness (VEINF), defined as the decrease in secondary transmissions from infected vaccine recipients versus from infected placebo recipients, is also not being measured. Using mathematical modeling of data from King County Washington, we demonstrate that if the Moderna and Pfizer vaccines, which have observed VEDIS>90%, mediate VEDIS predominately by complete protection against infection, then prevention of a fourth epidemic wave in the spring of 2021, and associated reduction of subsequent cases and deaths by 60%, is likely to occur assuming rapid enough vaccine roll out. If high VEDIS is explained primarily by reduction in symptoms, then VEINF>50% will be necessary to prevent or limit the extent of this fourth epidemic wave. The potential added benefits of high VEINF would be evident regardless of vaccine allocation strategy and would be enhanced if vaccine roll out rate is low or if available vaccines demonstrate waning immunity. Finally, we demonstrate that a 1.0 log vaccine-mediated reduction in average peak viral load might be sufficient to achieve VEINF=60% and that human challenge studies with 104 infected participants, or clinical trials in a university student population could estimate VESUSC, VESYMP and VEINF using viral load metrics.

Download data

  • Downloaded 2,207 times
  • Download rankings, all-time:
    • Site-wide: 11,242
    • In infectious diseases: 1,769
  • Year to date:
    • Site-wide: 9,746
  • Since beginning of last month:
    • Site-wide: None

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide